SomaLogic Company

SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.
Technology: Biotechnology, Health Care, Health Diagnostics, Medical Device
Industry: Clinical Development, Preclinical Development
Headquarters: Boulder, Colorado, United States
Founded Date: 2000-01-01
Employees Number: 251-500
Funding Status: IPO
Investors Number: 37
Total Funding: 956517993
Estimated Revenue: $50M to $100M
Last Funding Date: 2021-09-01
Last Funding Type: Post-IPO Equity

Visit Website
Register and Claim Ownership